Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Target Price
The average target price of ACE.ST is 1.93 and suggests 271% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc